Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable agonist of the nicotinic acetylcholine receptor (nAChR) with a Ki of 16.7 nM.

nAChR:16.7 nM(Ki), α6β2 nAChR:0.11 μM(EC50), α4β2 nAChR:17 nM(Ki,rat brain)

Pozanicline is a partial agonist at α4β2 nAChR. Moreover, one α6β2 nAChR subtype is particularly sensitive to Pozanicline (EC50 of 0.11 μM)[2]. Pozanicline shows high selectivity for α6β2 and α4α5β2 nAChR subtypes[3].

ABT-089, a partial agonist of α4β2*, and ABT-107, an α7 nicotinic acetylcholine receptor agonist, for amelioration of cognitive deficits induced by withdrawal from chronic nicotine in mice.?Mice underwent chronic nicotine administration (12.6 mg/kg/day or saline for 12 days), followed by 24 h of withdrawal.?At the end of withdrawal, mice received 0.3 or 0.6 mg/kg ABT-089 or 0.3 mg/kg ABT-107 (doses were determined through initial dose-response experiments and prior studies) and were trained and tested for CFC.?Nicotine withdrawal produced deficits in CFC that were reversed by acute ABT-089, but not ABT-107.?Cued conditioning was not affected.?modulation of hippocampal learning and memory using ABT-089 may be an effective component of novel therapeutic strategies for nicotine addiction[3].